Thus, a patient with NPM1-mutated AML who received VEN-AZA will have a favorable prognosis if TP53, KRAS, NRAS and FLT3-ITD are negative, while their prognosis will be intermediate in case of positivity of FLT3-ITD, KRAS and/or NRAS (Table 1) [78,79,80]. Here, KRAS is linked to acute myeloid leukemia.